Recursion Pharmaceuticals Inc. Class A Common Stock (RXRX)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I view Recursion as a clinical-stage drug-discovery platform, not a proven business. It has not earned a profit in the last four years, which is why the computed Lynch category is none. In fiscal 2025, the year ended 2025-12-31, revenue was $74.7 million, net income was -$644.8 million, and diluted EPS was -$1.44. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $7.7 million, net income was -$131.0 million, and diluted EPS was -$0.25. Revenue also fell from $19.2 million in fiscal Q2 2025, the quarter ended 2025-06-30, though net loss narrowed from -$171.9 million to -$131.0 million. The cash machine runs in reverse: trailing free cash flow is -$354.3 million, a -17.3% FCF yield. The one clear balance-sheet comfort is low debt, with D/E of 0.07. But FairStock calculations show P/B of 2.24, ROE of -56.58%, and a negative P/E because there are no earnings. FairStock's Piotroski F-Score of 3/9 and Altman Z-Score of 1.57 suggest financial weakness. At $3.84 on 2026-10-13, with a $2.1 billion market cap, the stock is near the low end of its 52-week range of $2.77-$7.18, but cheapness against no profits is not a margin of safety. I need evidence that the science can produce durable revenue or profits before calling this a sound value.

In plain English: Recursion is an early-stage drug company that uses computing and lab automation to try to discover new medicines. It is not profitable, loses much more than it earns, and its revenue is still small. At $3.84, the price does not look cheap against the current business, though the story could change if its drug programs succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer